Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.
Hohlbaum AM, Gille H, Trentmann S, Kolodziejczyk M, Rattenstetter B, Laarakkers CM, Katzmann G, Christian HJ, Andersen N, Allersdorfer A, Olwill SA, Meibohm B, Audoly LP, Swinkels DW, van Swelm RPL. Hohlbaum AM, et al. Among authors: olwill sa. Br J Pharmacol. 2018 Apr;175(7):1054-1065. doi: 10.1111/bph.14143. Epub 2018 Feb 23. Br J Pharmacol. 2018. PMID: 29329501 Free PMC article.
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.
Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L. Olwill SA, et al. Mol Cancer Ther. 2013 Nov;12(11):2459-71. doi: 10.1158/1535-7163.MCT-13-0318. Epub 2013 Sep 3. Mol Cancer Ther. 2013. PMID: 24002935
In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.
Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA. Terwisscha van Scheltinga AG, et al. Among authors: olwill sa. J Nucl Med. 2014 Apr;55(4):665-71. doi: 10.2967/jnumed.113.124941. Epub 2014 Mar 10. J Nucl Med. 2014. PMID: 24614223 Free article.
[No title available]
[No authors listed] [No authors listed] PMID: 35191488
The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
Peper-Gabriel JK, Pavlidou M, Pattarini L, Morales-Kastresana A, Jaquin TJ, Gallou C, Hansbauer EM, Richter M, Lelievre H, Scholer-Dahirel A, Bossenmaier B, Sancerne C, Riviere M, Grandclaudon M, Zettl M, Bel Aiba RS, Rothe C, Blanc V, Olwill SA. Peper-Gabriel JK, et al. Among authors: olwill sa. Clin Cancer Res. 2022 Aug 2;28(15):3387-3399. doi: 10.1158/1078-0432.CCR-21-2762. Clin Cancer Res. 2022. PMID: 35121624 Free PMC article.
Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity.
Kwok HF, Buick RJ, Kuehn D, Gormley JA, Doherty D, Jaquin TJ, McClurg A, Ward C, Byrne T, Jaworski J, Leung KL, Snoddy P, McAnally C, Burden RE, Gray B, Lowry J, Sermadiras I, Gruszka N, Courtenay-Luck N, Kissenpfennig A, Scott CJ, Johnston JA, Olwill SA. Kwok HF, et al. Among authors: olwill sa. Mol Cancer. 2011 Dec 14;10:147. doi: 10.1186/1476-4598-10-147. Mol Cancer. 2011. PMID: 22168338 Free PMC article.
23 results